Patent Filing

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A secretive Department of War initiative partners a quantum tech firm with special ops experts to deploy a revolutionary battlefield detection system.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

After 18 years, a judge ruled prosecutors hid key scientific evidence in the case of Deborah Nicholls, convicted of a fire that killed her three children.

The new platform integrates public records requests from intake to delivery, promising to ease the burden on agencies facing massive backlogs.

With a new permit, Falcon Gold targets a historic Ontario gold camp. Can modern drilling unlock a major discovery or is it another speculative play?

The cybersecurity firm released a new protocol for AI agent identity, a real-time zero-day tracker, and secured a key partnership with Anthropic.

The grooming brand's new military-themed razors offer discounts to service members, but the launch raises questions about patriotism, profit, and strategy.

A beloved nursing home, destroyed in the Eaton Fire, sues SoCal Edison, claiming the utility's negligence left 45 vulnerable residents permanently displaced.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

A junior miner strikes bonanza-grade silver and critical cobalt in a historic district, positioning itself to capitalize on a sixth straight year of market deficits.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

With cash burn rising, Summit Therapeutics races toward a November FDA decision on its novel cancer drug ivonescimab and a major data reveal at ASCO.

A new patent for a biomarker-guided therapy offers hope for millions with treatment-resistant depression and extends market exclusivity for decades.

Dallas legal icon Charla Aldous earns a Hall of Fame honor while her firm wages high-stakes fights for child safety and global corporate accountability.

Gentherm reports a record $394M first quarter, beating estimates as its transformational Modine deal progresses and it enters new medical and home markets.

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.